Serum sclerostin levels associated with lumbar spine bone mineral density and bone turnover markers in patients with postmenopausal osteoporosis

作     者：XU Xiao-juan SHEN Lin YANG Yan-ping LU Fu-rong ZHU Rui SHUAI Bo LI Cheng-gang WU Man-xiang 

作者机构：Department of Integrated Traditional Chinese Medicine and Western Medicine Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei 430022 China 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2013年第126卷第13期

页      面：2480-2484页

核心收录：

学科分类：0710[理学-生物学] 090603[农学-临床兽医学] 1002[医学-临床医学] 07[理学] 09[农学] 0906[农学-兽医学] 071007[理学-遗传学] 

基　　金：This study was supported by grants from the National Natural Science Foundation of China （No. 81072943） and Health Department of Hubei Province （No. 2012Z-Z01）. 

主　　题：sclerostin,＂ postmenopausal osteoporosis bone mineral density 

摘      要：Background Sclerostin, expressed exclusively by osteocytes, is a negative regulator of bone formation. To gain insights into the action of sclerostin in postmenopausal osteoporosis, we evaluated serum sclerostin levels in postmenopausal women and investigated its possible associations with bone turnover markers in patients with postmenopausal osteoporosis. Methods We detected serum sclerostin, and measured lumbar spine bone mineral density in 650 Chinese postmenopausal women. We also assessed serum levels of 13-isomerized C-terminal crosslinking of type I collagen, intact N-terminal propeptide of type I collagen, N-mid fragment of osteocalcin, 25-hydroxyvitamin D, and estradiol. Results Serum sclerostin levels were lower in postmenopausal osteoporotic women compared with non-osteoporotic postmenopausal women （（38.79＋7.43） vs. （52.86＋6.69） pmol/L, P 〈0.001）. Serum sclerostin was positively correlated with lumbar spine bone mineral density （r=0.391, P 〈0.001） and weakly negatively correlated with [3-isomerized C-terminal crosslinking of type I collagen, intact N-terminal propeptide of type I collagen, N-mid fragment of osteocalcin （t= -0.225, P 〈0.001; r= -0.091, P=0.046; r= -0.108, P=0.018; respectively） in postmenopausal osteoporosis. There was no significant association of serum sclerostin with age, body mass index, 25-hydroxyvitamin D, and estradiol （r= -0.004, P=0.926; r=0.067, P=0.143; r=0.063, P=0.165; r= -0.045, P=0.324; respectively）.Conclusion Sclerostin may be involved in the pathogenesis of postmenopausal osteoporosis and may play a role in bone turnover.